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Introduction
Helicobacter pylori is a Gram-negative spiral bacterium. Its
association with gastritis, gastric and duodenal ulcers, gastric
adenocarcinoma and mucosa-associated lymphoid tissue
(MALT) lymphoma is well established,1 and has a worldwide
distribution. Seroprevalence of H. pylori in Karachi, Pakistan,
in healthy children aged 11–15 years is reported as 53.5%.2
Successful eradication of H. pylori infection requires the
use of an antibiotic regimen to which the infecting strain is
susceptible.3 The Maastricht consensus report on H. pylori
advised that the first-line treatment should be a drug
regimen that includes a proton pump inhibitor (PPI) and
two antimicrobial agents (clarithromycin plus amoxicillin or
clarithromycin plus metronidazole).4 The triple therapy
usually results in an eradication rate >80%.
In recent years, the emergence of antibiotic-resistant 
H. pylori strains has been reported, posing a significant
threat to successful treatment.3,5–6 In a previous multicentre
study in patients with active duodenal ulcer, one week of
triple therapy with PPI, amoxicillin and clarithromycin
eradicated H. pylori infection.7 Low cure rate and a higher
resistance to clarithromycin have been observed among 
H. pylori-positive patients with functional dyspepsia.8–10
In practice, H. pylori infection currently is being treated in
most centres in Pakistan without knowledge concerning the
incidence of resistant strains. For most bacterial infections,
antibiotic susceptibility testing is routinely carried out but the
specialised growth requirements of H. pylori preclude such
tests in most diagnostic medical laboratories. There is limited
local published information that includes data on the
antibiotic susceptibility of this pathogen.11–12 In a study
conducted in the north of Pakistan, the antimicrobial
susceptibility of H. pylori isolates from 43 specimens
determined by the Kirby Bauer technique against amoxycillin,
clarithromycin and metronidazole demonstrated that 67%
were resistant to metronidazole, while all the isolates were
sensitive to amoxycillin, clarithromycin and tetracycline.12
The aim of this study is to determine the effect of primary
H. pylori resistance to antibiotics used for triple therapy that
included clarithromycin (CLR, 500 mg), amoxicillin (AMX, 
1 g) and omeprazole (40 mg) twice a day for two weeks, and
its effect on eradication of H. pylori in patients with non-
ulcer dyspepsia (NUD) and peptic ulcer disease (PUD).
Eradication was documented by performing a 14C-urea
breath test (14C-UBT) four weeks after completion of
treatment. Also determined is the prevalence of 23S
ribosomal RNA (rRNA) point mutations associated with
clarithromycin resistance in H. pylori isolates.
Materials and methods 
H. pylori strains
Over the 24 months of the study period (February 2007 to
January 2009), a total of 92 H. pylori isolates were obtained
from patients referred for endoscopy at the Aga Khan
Antibiotic susceptibility patterns of Helicobacter
pylori and triple therapy in a high-prevalence area 
J. YAKOOB, S. ABID, Z. ABBAS and S. N. W. JAFRI
Department of Medicine, The Aga Khan University, Karachi, Pakistan
ABSTRACT
This study aims to determine primary Helicobacter pylori
resistance and its effect on eradication of the organism.
Ninety-two patients with dyspeptic symptoms were
enrolled. H. pylori was cultured and antibiotic sensitivity
was determined by the Epsilometer test (Etest) for
clarithromycin (CLR), amoxicillin (AMX) and
metronidazole (MTR). 23S ribosomal RNA (rRNA) point
mutations associated with clarithromycin resistance were
also detected. Patients were treated with omeprazole 
(40 mg daily), CLR (500 mg) and AMX (1g twice a day) for
14 days. A 14C-urea breath test (14C-UBT) was repeated four
weeks after completion of treatment to confirm
eradication. Triple therapy failure was seen in 30(33%)
patients. The resistance rates were: CLR 33% (30/92), MTR
48% (44/92) and AMX 2% (2/92). Clarithromycin resistance
(CLR-R) was present in the 16–39 age group in 21 (47%)
(P=0.007) compared to nine (19%)in the 40–79 age group.
CLR resistance was seen in 30 H. pylori isolates, 20 (67%)
from patients with non-ulcer dyspepsia (NUD), six (20%)
with gastric ulcer (GU) and four (13%) with duodenal ulcer
(DU). Triple therapy failure was associated with CLR-R in
28 (93%) (P<0.001). CLR-R mutations were present in 
30 (33%) and were associated with treatment failure in 
27 (90%; P<0.001). They were present in 20 (44%) isolates
obtained from patients in the 16–39 age group (P=0.018).
Treatment failure was associated with A2142G mutation 
in 20 (67%; P<0.001), A2143G mutation in 12 (40%;
P<0.001) and A2142C mutation in five (17%; P=0.003). 
In conclusion, triple therapy failure was associated with
CLR-R. Metronidazole resistance exceeded that of CLR,
hence it cannot be substituted for CLR in a triple therapy.
KEY WORDS: Clarithromycin. 
Drug resistance, microbial. 
Helicobacter pylori. 
Metronidazole. 
Correspondence to: Dr Javed Yakoob 
Department of Medicine, The Aga Khan University Hospital, Stadium Road,
Karachi-74800, Pakistan 
Email yakoobjaved@hotmail.com
ORIGINAL ARTICLE 197
BRITISH JOURNAL OF BIOMEDICAL SCIENCE 2010  67 (4)
University (Table 1). Inclusion criteria comprised a history of
upper abdominal pain requiring histological definition,
symptoms suggestive of peptic ulcer, and where gastric
biopsy was indicated by endoscopy finding. Ethical
approval for the collection of extra biopsies was granted by
the Aga Khan University Ethics Review Committee.
Upper endoscopy was performed and gastric biopsy
samples were obtained in triplicate from within 5 cm of the
pylorus along the greater curvature for culture and
histopathology. H. pylori infection was defined by i) positive
culture, ii) positive histopathology, and iii) positive rapid
urease test.
Culture and identification of H. pylori
The specimens were transported immediately in sterile
normal saline to isolate H. pylori. Thus, within three hours of
collection each specimen was homogenised in sterile
Eppendorf tubes with an electric homogeniser. The resulting
suspension was inoculated onto Columbia blood agar
(Oxoid) medium and Dents supplement (containing
vancomycin, trimethoprim and polymyxin) and incubated
at 37˚C under microaerophilic conditions for 4-6 days. Plates
were then examined for bacterial growth and typical
colonies were selected for identification. The identity of 
H. pylori was confirmed by Gram stain and by the
production of urease and catalase. One half of the
homogenate was used for culture and the other half was
kept at -80˚C. H. pylori isolates were defined as Gram-
negative spiral-shaped bacilli that were catalase-positive
and rapidly (less than 1 h) urease-positive. H. pylori NCTC
11637 (type strain) was used as a positive control for the
culture conditions and identification tests.
Antibiotic susceptibility testing
Antibiotic susceptibility was determined on Mueller Hinton
agar (Oxoid, UK) containing 10% defibrinated sheep blood
and a cell suspension calibrated at three McFarland units by
Epsilometer test (Etest) using metronidazole, clarithromycin
and amoxycillin Etest strips (AB Biodisk, Solna, Sweden).
Plates were read after three days at 37˚C. The tests 
were carried out according to the manufacturer ’s
instructions. For Etests, minimum inhibitory concentration
(MIC) breakpoints of ≥2 mg/L and ≥8 mg/L were used for
metronidazole and clarithromycin, respectively.
Intermediate susceptibility (MIC 2–8 mg/L) was also
recorded for metronidazole. High-level resistance to both
antibiotics was defined as MIC >256 mg/L. The breakpoint
MIC used for amoxicillin was ≥2 mg/L.13 H. pylori NCTC
11637 was used as a sensitive control.
Rapid urease test 
Urea agar base enriched with 40% urea solution (eUAB,
Oxoid) was used as a rapid urease test.14 It shows 97%
sensitivity, 86% specificity, 84% positive predictive value
(PPV), 97% negative predictive value (NPV) and 91%
accuracy to detect urease activity of H. pylori in gastric
biopsy.
Histological analysis
Formalin-fixed, paraffin wax-embedded gastric biopsy
specimens were routinely processed. Gastritis activity 
was graded on a four-point scale of none (grade 0), mild
(grade 1), moderate (grade 2), and severe (grade 3)
according to the guidelines of the Sydney system.15 Presence
of H. pylori was assessed on modified Giemsa-stained
sections. 
Urea breath test
A 14C-UBT procedure was undertaken using methodology
described previously.16 In a previous study, the accuracy of
14C-UBT was compared to histopathology and rapid urease
test. Accuracy was 93% compared to histopathology, while
PPV and NPV were 97% and 84%, respectively.17
Comparison of 14C-UBT with rapid urease test gives an
accuracy of 96%, with PPV and NPV of 95% and 97%,
respectively. These results were highly reproducible
(P<0.001).17
Extraction of genomic DNA
Bacterial cells grown on chocolate agar were washed (x2)
with phosphate-buffered saline (PBS) then centrifuged at
3000 xg for 20 min. H. pylori DNA was extracted by a
phenol/chloroform method as described previously.18 Briefly,
the bacterial pellet was resuspended in Tris-HCl buffer
containing ethylenediaminetetraacetate (TE, pH 8.0) and
lysozyme (30 mg/mL) and then incubated at 37˚C for 30 min.
The suspension was treated with sodium dodecyl sulphate
(SDS, 10%), proteinase K (2.5 mg/mL) and RNase A (40 mg/mL).
DNA was extracted with phenol/chloroform/isoamyl
alcohol, precipitated by sodium acetate and ice-cold absolute
alcohol, and the washed with ice-cold alcohol (70%). The
DNA pellet was resuspended in TE buffer. The DNA content
and purity were determined by measuring absorbance at 
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Age Mean ±SD 43±15
Range 16–79
Age group 16–39 years 43(47)
Age group 40–79 years 49(53)
Gender Male 62(67)
Female 30(33)
Symptoms Abdominal pain 46(83)
Heartburn 5(5)
Diarrhoea 8(9)
Haematemesis 3(3)
Diagnosis Non-ulcer dyspepsia 57(62)
Gastric ulcer 15(16)
Duodenal ulcer 20(22)
14C Urea breath test Positive 30(33)
Negative 62(67)
Clarithromycin Sensitive 62(67)
Resistant 30(33)
Metronidazole Sensitive 48(52)
Resistant 44(48)
Amoxicillin Sensitive 90(98)
Resistant 2(2)
Data shown as patient numbers (%). 
Results presented as mean±standard deviation for 
quantitative variables. 
Table 1. Characteristics of the study patients from which H. pylori
isolates were obtained.
260 nm and 280 nm using a spectrophotometer (Beckman
DU-600, USA).
Polymerase chain reaction
A 267 bp fragment was amplified by PCR using extracted
DNA as the template, as previously described, using 
primers 5’-AGGTTAAGAGGATGCGTCAGTC-3’ (HPY-S) 
and 5’-CGCATGATATTCCCATTAGCAGT-3’ (HPY-A),
corresponding to nucleotides 1931–1952 and 2197–2175,
respectively, of the 23S rRNA gene of H. pylori (GenBank
Accession No U27270).19 Amplification was carried out in a
total volume of 50 mL containing 1xPCR reaction buffer,
1.5 mmol/L MgCl2, 200 µmol/L each of four dNTPs, 
0.2 mmol/L primers (synthesised by MWG), 2 unit of
Thermus aquaticus (Taq) DNA polymerase (Promega) and 
2 mL extracted DNA. The reaction was carried out in a
Perkin Elmer 9700 thermal cycler. Amplification cycle
comprised an initial denaturation of target DNA at 94˚C for
5 min and then denaturation at 94˚C for 1 min, primer
annealing at 55˚C for 1 min and extension at 72˚C for 1 min.
The final cycle included an extension step for 7 min at 72˚C
to ensure full extension of the product. The samples were
amplified through 35 consecutive cycles. Negative reagent
control reactions were performed with each batch of
amplifications, consisting of tubes containing DNA isolated
from H. pylori-negative patients. After amplification, PCR
products were precipitated and the pellets washed in 70%
ethanol and resuspended in 25 µL sterile distilled water. 
The PCR products (3 µL) were subjected to electrophoresis
in 2% agarose gel to ensure homogeneity and yield.
Amplification resulted in a homogeneous DNA fragment of
the expected size. 
The amplified products obtained were subjected to
restriction endonuclease digestion for 2 h at 37˚C in a 20 µL
volume.20 The digested samples were analysed by agarose
gel (3% [w/v]) electrophoresis. Restriction enzymes BbsI
(5 units), BsaI (5 units) and BceAI (0.5 units) (New 
England Biolabs) were used on the basis of sequence data
available for this amplified product. Restriction fragment
length polymorphism (RFLP) allowed the identification 
of the A2142G and A2143G mutations using the BbsI
and BsaI restriction enzymes, respectively, as previously
described.21,22 The enzyme BceAI recognised, on the 267 bp
amplified product, two sites 5’-ACGGC(N)122N-‘3 and 
5’-N2(N)12GCCGT-3’, yielding two restriction fragments
from the wild-type and three from the A2142G and 
A2143G mutants (195, 48 and 24), while BceAI yielded four
from the A2142C mutation, recognising an additional site, 
5’-ACGGC(N)122N-3’. The amplified PCR products were
resolved in 3% agarose gel containing Tris/acetate/EDTA,
stained with ethidium bromide and visualised under an
ultraviolet light source.
Statistical assessment
The Statistical Package for Social Science (SPSS, Release 16,
standard version) was used for data analysis. Results were
presented as mean±standard deviation (SD) for quantitative
variables and number (%) for qualitative variables.
Differences in proportion were assessed using Pearson's χ2,
Fisher exact or likelihood ratio tests where appropriate.
P<0.05 was considered statistically significant. 
Results
Triple therapy failure was seen in 30(33%) patients. The
primary antibiotic resistance rates are shown in Table 1. Dual
resistance to CLR and AMX was present in two (2%) cases, to
CLR and MTR in 13 (14%), and one patient showed
resistance to all three antibiotics.
Sensitivity and resistance data by age group are shown in
Table 2. Dual resistance to CLR and MTR was seen in 
11( 85%) patients in the 16–39 ago group compared to two
(15%) in the 40–79 age group (P=0.007). The resistance rate
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Clarithromycin Metronidazole Amoxicillin
Sensitive Resistant P value Sensitive Resistant P value Sensitive Resistant P value
(n=62) (n=30) (n=48) (n=44) (n=90) (n=2)
Age groups 16–39 years 24(53) 21(47) 0.005 22(49) 23(51) 0.537 44(98) 1(2) 0.975
40–79 years 38(81) 9 (19) 26(55) 21(45) 46(98) 1(2)
Diagnosis Mean age
Non-ulcer dyspepsia 40±15 37(65) 20(35) 30(53) 27(47) 56(98) 1(2)
Gastric ulcer 46±15 9(60) 6(40) 0.725 4(27) 11(73) 0.088 14(93) 1(7) 0.376
Duodenal ulcer 45±13 16(80) 4(20) 0.269 14(70) 6(30) 0.177 20(100) 0(0)
14C Urea breath test Positive 2(7) 28(93) <0.001 16(53) 14(47) 0.877 29(97) 1(3) 0.548
Negative 60(97) 2(3) 32(52) 30(48) 61(98) 1(2)
Data shown as patient numbers (%).
P<0.05 was considered statistically significant. 
Table 2. Distribution of antibiotic sensitivities.
Fig. 1. Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) pattern of 23S rRNA genes from
patients with clarithromycin resistance. Lane M, DNA size marker;
PCR-RFLP pattern obtained with Bbs1 (lane A), BceA1 (lane B)
and Bsa1 (lane C).
M A B C
200 bp
100 bp
to CLR and MTR did not show a gender distribution.
Correlation of diagnosis with antibiotic susceptibilities is
shown in Table 2, as is association with triple therapy failure,
which was associated with resistance to CLR in 28 (93%)
cases (P<0.001). A breakdown of treatment failure is shown
in Table 3. Details of the correlation between treatment
failure and mutation is shown in Figure 1 and Table 3.
The CLR resistance mutations were present in 30 (33%) 
H. pylori isolates. These mutations were associated with
treatment failure in 27(90%) cases (P<0.001). These
mutations were present in 20 (44%) H. pylori isolates from
patients in the 16–39 age group and 10 (21%) in the 40–79 age
group (P=0.018), and were present in 19 (33%) patients with
NUD, four (20%) with DU (P=0.262) and seven (47%) with
GU (P=0.339). 
Discussion
This study demonstrated a triple therapy failure rate of 30%.
It was found more frequently in those under 40 years of age
who had NUD. However, the difference was not significant
in those with NUD compared to those with PU. Resistance
to AMX was seen in a small number of patients, while MTR
is not used locally as a part of triple therapy for H. pylori
infection, although it is commonly prescribed for infectious
diarrhoea of both bacterial and parasitic origin. 
The implication of this study is that there is a high degree
of MTR resistance in H. pylori isolates so it cannot be used
instead of CLR in triple therapy regimens. Metronidazole
resistance may be associated with previous use of the drug.23
In contrast to the findings reported here, Mirza et al., from
the north of Pakistan, reported 100% sensitivity to CLR and
AMX, which shows that resistance to CLR has evolved in the
south of the country.12
Clarithromycin resistance may be associated with pre-
existent resistance to other macrolides (e.g., erythromycin)
or infection with H. pylori strains with DNA mutations
associated with CLR resistance. These mutations are known
to be associated with different MIC values in vitro. A very
low eradication rate (48%) occurred in the A2143G mutated
strains, while the rate was higher than 90% in the absence 
of this mutation.23 In addition to use in the treatment of 
H. pylori infection, CLR is commonly prescribed for the
treatment of acute exacerbation of chronic bronchitis in
adult patients in the community. In Pakistan, self-
prescription is also common and medications are available
for sale without prescriptions.24,25 
Erythromycin is among the most frequently used agents.24
High levels of resistance have been found to ampicillin, co-
trimoxazole and erythromycin.25 Poultry use has increased
with rising inflation, and poultry production largely
depends on the use of antibiotics, and erythromycin is
commonly used.26 Owing to indiscriminate use and
unawareness of adequate withdrawal periods, antibiotic
residues are known to be present in the meat. This is unfit
for human consumption and known to alter intestinal
bacterial flora and encourage the development of resistant
bacteria.27 Akhtar et al. cultured 58 isolates of Salmonella
enteritidis from stool samples of patients with diarrhoea, all
of which showed resistance to erythromycin.28
South Asia is a low-risk region for gastric cancer but has a
high prevalence of H. pylori.29 Locally, the incidence of gastric
carcinoma has been increasing, markedly in males over 40
years of age.29 A recent study concluded that primary care
physicians lacked knowledge regarding the management of
H. pylori infection.30 Only 57% would confirm H. pylori
eradication after treatment in selected patients, and 47%
physicians preferred serological testing for follow-up. 
In conclusion, this study has shown that MTR resistance
exceeds CLR resistance in H. pylori isolates from patients
with upper gastrointestinal symptoms. In view of this
finding, MTR cannot be used in place of CLR in patients who
demonstrate CLR-based triple therapy failure. 5
This study was supported by a research grant from URC of the Aga
Khan University to JY and SA.
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